Table 2.

Associations between quartiles of baseline plasma FGF-23 concentrations with specific cardiovascular events

FGF-23 concentrationsQ1 ≤216 RU/mlQ2 217–380 RU/mlQ3 381–945 RU/mlQ4 >946 RU/ml
Myocardial Infarction
No. Myocardial Infarction25354340
Hazard Ratio (95% CI)
    Model 11.001.61 (0.96–2.70)2.31 (1.40–3.81)2.52 (1.49–4.26)
    Model 21.001.52 (0.88–2.63)1.95 (1.09–3.50)2.17 (1.13–4.15)
    Model 31.001.58 (0.91–2.76)2.10 (1.15–3.81)2.44 (1.25–4.76)
Amputation
No. Amputation391418
Hazard Ratio (95% CI)
    Model 11.003.46 (0.93–12.84)5.73 (1.63–20.12)8.15 (2.33–28.47)
    Model 21.003.01 (0.75–12.13)4.01 (0.98–16.50)6.01 (1.38–26.12)
    Model 31.003.35 (0.81–13.9)4.75 (1.12–20.14)7.00 (1.54–31.83)
Stroke
No. Strokes1110913
Hazard Ratio (95% CI)
    Model 11.000.94 (0.40–2.23)0.92 (0.37–2.25)1.40 (0.60–3.29)
    Model 21.000.63 (0.26–1.55)0.44 (0.15–1.27)0.76 (0.26–2.27)
    Model 31.000.59 (0.23–1.46)0.41 (0.14–1.19)0.78 (0.26–2.35)
  • Model 1 adjusted for age, gender, race. Model 2 adjusted for covariates in Model 1 plus smoking, alcohol intake, diabetes, hypertension, prevalent cardiovascular disease, Charlson score, body mass index, systolic and diastolic blood pressures, homocysteine, folate, vitamin B12, treatment arm, hemoglobin, estimated glomerular filtration rate, albumin, calcium, phosphorus, 25-hydroxyvitamin D, 1,25 dihydroxyvitamin D, intact parathyroid hormone, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides. Model 3 adjusted for covariates in Model 2 plus use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta blockers, aldosterone antagonists, lipid-lowering agents, aspirin, anticoagulants, anti-arrhythmic drugs, and sevelamer. Quartile 1 is the reference group in all models.